Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6

Journal of Periodontal Research

Volumn 46, Issue 1, 2011, Pages 39-47

  Tipton, D A ^a   Seshul, B A ^b   Dabbous, M Kh ^a,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b USAF   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Bone; Fibroblasts; Osteonecrosis of the jaw

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID;

ANALYSIS OF VARIANCE; ARTICLE; BIOSYNTHESIS; BONE REMODELING; CELL CULTURE; CYTOLOGY; DRUG EFFECT; FIBROBLAST; GINGIVA; HUMAN; METABOLISM; NECROSIS; NONPARAMETRIC TEST; OSTEOCLAST; PHYSIOLOGY;

ALENDRONATE; ANALYSIS OF VARIANCE; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CELLS, CULTURED; DIPHOSPHONATES; FIBROBLASTS; GINGIVA; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; NECROSIS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; STATISTICS, NONPARAMETRIC;

EID: 78650868239     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2010.01306.x     Document Type: Article

References (57)

1. Ruggiero S, Grabow J, Marx RE et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006;2:7-14.
2. Assael L. New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg 2004;62:125-126.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
4. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:527-534.
5. Kuehn BM. Reports of adverse events from bone drugs prompt caution. J Am Med Assoc 2006;295:2833-2836.
6. Markiewicz MR, Margarone JE III, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 2005;136:1669-1674.
7. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005;39:668-677.
8. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo S-B. Managing the care of patients with bisphosphonate-associated osteonecrosis. JADA 2005;136:1658-1668.
9. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117.
10. Russell RG, Rogers MJ, Frith JC et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999;14:53-65.
11. Sato M, Grasser W, Endo N et al. Bisphosphonate action: Alendronate localization in rat bone and effects on oteoblast ultrastructure. J Clin Invest 1991;88:2095-2105.
12. Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 2005;328:709-720.
13. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301.
14. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
15. Wong BR, Josien R, Lee SY et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNK family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-2080.
16. Ishimi Y, Miyaura C, Jin CH et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990;145:3297-3303.
17. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
18. Viereck V, Emons G, Lauck V et al. Bisphosphonates pamidronate and zoledronic acid stimulated osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-686.
19. Guiliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production of human osteoblast-like cells. Scand J Rheumatol 1998;27:38-41.
20. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-463.
21. Rani CS, MacDougall M. Dental cells express factors that regulate bone resorption. Mol Cell Biol Res Commun 2000;3:145-152.
22. Nagasawa T, Kobayashi H, Kiji M et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. Clin Exp Immunol 2002;130:338-344.
23. Wada N, Maeda H, Yoshimine Y, Akamine A. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone 2004;35:629-635.
24. Takahashi K, Takashiba S, Nagai A et al. Assessment of interleukin-6 in the pathogenesis of periodontal disease. J Periodontol 1994;65:147-153.
25. Tipton DA, Pabst MJ, Dabbous MKh. Interleukin-1ß- and tumor necrosis factor α-independent monocyte stimulation of fibroblast collagenase activity. J Cell Biochem 1990;44:253-264.
26. Lowry OH, Rosebrough NJ, Farr L, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-275.
27. Oyama VI, Eagle H. Measurement of cell growth in tissue culture with a phenol reagent (Folin-Ciocalteau). Proc Soc Exp Biol Med 1956;91:305-307.
28. 2 and IL-6 production by human gingival fibroblasts. J Periodontol 2003;74:1754-1763.
29. Yasuda H, Shima N, Nakagawa N et al. A novel molecular mechanism modulating osteoblast differentiation and function. Bone 1999;25:109-113.
30. Woo S-B, Hellstein J, Kalmar J. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Int Med 2006;144:753-761.
31. Reid I, Bolland M, Grey A. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-320.
32. Kyrgidis A, Triardis S, Antoniades K. Effects of bisphosphonates on keratinocytes and fibroblasts having a role in the development of osteonecrosis of the jaw. Biosci Hypotheses 2009;2:153-159.
33. Rubegni P, Fimiani M. Bisphosphonate-associated contact stomatitis. N Engl J Med 2006;355:E25-E25.
34. Derenne S, Amiot M, Barillé S et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999;14:2048-2056.
35. Correia V, Caldeira C, Marques M et al. Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament fibroblasts. Dent Traumatol 2006;22:312-317.
36. Garcia Moreno C, Serrano S, Nacher M et al. Effect of alendronate on cultured normal human osteoblasts. Bone 1998;22:233-239.
37. Pan B, Farrugia A, To L et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004;19:147-154.
38. Chen T, Berenson J, Vescio R et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-1238.
39. Usui T, Tanaka S, Sonoda T et al. Drug disposition of incadronate, a new bisphosphonate, in rats with bone metastases. Xenobiotica 1997;27:479-487.
40. Morton RS, Dongari-Bagtzoglou AI. Regulation of gingival fibroblast interleukin-6 secretion by cyclosporine A. J Periodontol 1999;70:1464-1471.
41. Aida Y, Kukita T, Takada H, Maeda K, Pabst MJ. Lipopolysaccharides from periodontal pathogens prime neutrophils for enhanced respiratory burst: differential effect of a synthetic lipid A precursor IVA (LA-14-PP). J Periodont Res 1995;30:116-123.
42. Tipton D, Pabst M, Thomas E, Babu J, Stein S, Fry H. Association of high levels of Prevotella intermedia with aggressive periodontitis in a 16-year-old female. PERIO 2006;3:115-122.
43. Thiebaud D, Sauty A, Burckhardt P et al. An in vivo and in vitro study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997;61:386-392.
44. 2 synthesis in the clonal osteoblast-like cell line MC3T3-E1. Prostaglandins Leukot Essent Fatty Acids 1997;56:121-125.
45. 2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187. Methods Find Exp Clin Pharmacol 2006;28:361-367.
46. Xiao W, Hodge DR, Wang L, Yang X, Zhang X, Farrar WL. Co-operative functions between nuclear factors NFkB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 2004;61:354-370.
47. Irwin CR, Myrillas TT. The role of IL-6 in the pathogenesis of periodontal disease. Oral Dis 1998;4:43-47.
48. Martini G, Gennari L, Merlotti D et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 2007;40:457-463.
49. Hormdee D, Nagasawa T, Kiji R et al. Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. Clin Exp Immunol 2005;142:490-497.
50. Takami M, Takahashi N, Udagawa N et al. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-κB ligand and osteoprotegrin in osteoblasts. Endocrinol 2000;141:4711-4719.
51. Mackie P, Fisher J, Zhou H, Choong P. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001;84:951-958.
52. Tristano A, Fuller K. Immunomodulatory effects of statins and autoimmnune rheumatic diseases: Novel intracellular mechanism involved. Int Immunopharmacol 2006;6:1833-1846.
53. Kanzaki H, Chiba M, Shimizu Y, Mitani H. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. J Dent Res 2001;80:887-891.
54. Liu D, Xu J, Figliomeni L et al. Expression of RANKL and OPG mRNA in periodontal disease: Possible involvement in bone destruction. Int J Mol Med 2003;11:17-21.
55. Bostanci N, Ilgenli T, Emingl G et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Perio 2007;34:370-376.
56. Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-κB signaling pathways. J Biol Chem 2008;283:11535-11540.
57. Lindhe J, Karring T, Araujo M. Anatomy of the periodontium. In: Lindhe J, Karring T, Lang NP, eds. Clinical periodontology and implant dentistry. Oxford: Blackwell Munksgaard, 2003:3-49.